Patients recruited in Europe
Patients with suspected or proven Influenza in the UK
Active sites in Europe
Paediatric patients
in the UK
Active sites in
the UK
Numbers last updated on 9th September 2026.
The Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) was conceived after the 2009 Influenza AH1N1 (“Swine flu”) outbreak. During that pandemic and previous ones, the research response has been largely absent. REMAP-CAP was set up as an Adaptive Platform Trial embedded in clinical care that allows multiple therapies to be evaluated at the same time under a master protocol. In Europe, the trial is currently running in 15 countries.
